跳至主要内容
临床试验/NCT00539396
NCT00539396已完成2 期

A Phase 2 Randomized, Open Label, Multi-Center Study of the Use of Prandial Inhaled Technosphere Insulin in Combination With Basal Subcutaneous Lantus as Basal Insulin Versus Prandial Subcutaneous NovoRapid in Combination With Basal Subcutaneous Lantus Insulin in Subjects With Type 1 Diabetes Mellitus

Mannkind Corporation0 个研究点目标入组 110 人开始时间: 2005年3月最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
110
主要终点
Change in blood glucose following a standard meal

研究概览

简要总结

A 3 month, randomized, open label, multi-center study of Technosphere/Insulin compared to insulin aspart in subjects with type 1 diabetes mellitus receiving insulin glargine

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Type 1 diabetes currently receiving SC insulin at mealtimes for at least 3 months
  • BMI <40 kg/m squared
  • HbA1c greater than or equal to 7% and less than or equal to 11.5%
  • Serum creatinine less than 2 for males and less than 1.8 for females
  • Acceptable pulmonary function

排除标准

  • Significant hepatic disease
  • Previously diagnosed pulmonary disease, ketoacidosis of evidence of severe secondary complications of diabetes

结局指标

主要结局

Change in blood glucose following a standard meal

时间窗: 0-300 minutes

次要结局

  • Mean change from baseline HbA1c(week 12)

研究者

申办方类型
Industry

相似试验